NEW YORK (Reuters) – Weightwatchers announced on Tuesday the appointment of Kim Boyd to the post of medical director, the American group in difficulty adding to plan a new program to help women to cross menopause, as part of its recovery strategy.
Reuters had reported exclusively earlier this appointment earlier, which occurs almost a year after the departure of the previous medical director, Amy Meister.
Kim Boyd, a graduate of the University of Stanford and passed by several start-ups specializing in consumer health, said during an interview that Weightwatchers was based on its decades of weight management expertise to meet the specific needs of people using obesity treatments, such as the Wegovy of Novo Nordisk and the Zepbound of Eli Lilly.
Weightwatchers, which has marketed its weight loss programs to millions of members around the world, has been faced in recent years with the emergence of GLP-1’s analogues and placed in May under the protection of chapter 11 of the Bankruptcy Act in the United States.
The program for perimenopause, menopause and postmenopause will include access to prescription treatments such as substitutive hormone therapy, as well as behavioral and nutritional support for members, a significant proportion of which are women aged 40 to 60, according to Weightwatchers.
(Amina Niasse, Elena Smirnova, edited by Augustin Turpin)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
